NUMBL, NUMB like endocytic adaptor protein, 9253

N. diseases: 14; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.310 GeneticVariation disease BEFREE When the Brazilian and Danish cohorts were merged, a total of 1084 subjects, we found the allele 18 CAG of NUMBL (p=0.003, x2=8.88, OR=1.30, 95% CI 1.09-1.56) as well as the 18/18 CAG genotype (p=0.002, x2=9.46, OR=1.46, 95% CI 1.15-1.87) to be associated with schizophrenia. 16899352 2006
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.310 Biomarker disease PSYGENET When the Brazilian and Danish cohorts were merged, a total of 1084 subjects, we found the allele 18 CAG of NUMBL (p=0.003, x2=8.88, OR=1.30, 95% CI 1.09-1.56) as well as the 18/18 CAG genotype (p=0.002, x2=9.46, OR=1.46, 95% CI 1.15-1.87) to be associated with schizophrenia. 16899352 2006
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.100 GeneticVariation disease GWASCAT Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. 28604730 2017
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 GeneticVariation disease GWASCAT Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. 27515689 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.070 Biomarker disease BEFREE CDRP was applied on Illumina RNA-Seq of 498 Neuroblastoma patients (HR: 176) from the SEQC study (12,464 Entrez genes) and on Affymetrix Human Exon Array expression profiles (17,450 genes) of 247 primary diagnostic Neuroblastoma of the TARGET NBL cohort. 30532223 2018
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.070 Biomarker disease BEFREE CDRP was applied on Illumina RNA-Seq of 498 Neuroblastoma patients (HR: 176) from the SEQC study (12,464 Entrez genes) and on Affymetrix Human Exon Array expression profiles (17,450 genes) of 247 primary diagnostic Neuroblastoma of the TARGET NBL cohort. 30532223 2018
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.070 Biomarker disease BEFREE CDRP was applied on Illumina RNA-Seq of 498 Neuroblastoma patients (HR: 176) from the SEQC study (12,464 Entrez genes) and on Affymetrix Human Exon Array expression profiles (17,450 genes) of 247 primary diagnostic Neuroblastoma of the TARGET NBL cohort. 30532223 2018
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.070 Biomarker disease BEFREE One MNA (NBL-W) and one non-MNA neuroblastoma cell line (SKNSH) were sub-cloned into N and S-type cells and the p53 pathway investigated after irradiation induced DNA damage. 22052359 2011
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.070 Biomarker disease BEFREE One MNA (NBL-W) and one non-MNA neuroblastoma cell line (SKNSH) were sub-cloned into N and S-type cells and the p53 pathway investigated after irradiation induced DNA damage. 22052359 2011
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.070 Biomarker disease BEFREE One MNA (NBL-W) and one non-MNA neuroblastoma cell line (SKNSH) were sub-cloned into N and S-type cells and the p53 pathway investigated after irradiation induced DNA damage. 22052359 2011
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.070 Biomarker disease BEFREE In an effort to identify the genes and biological pathways that are responsible for the impaired NB tumor growth observed after treatment with 5-Aza-dC, we performed genome-wide gene expression analysis of control and treated NBL-W-S NB cells. 15231663 2004
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.070 Biomarker disease BEFREE In an effort to identify the genes and biological pathways that are responsible for the impaired NB tumor growth observed after treatment with 5-Aza-dC, we performed genome-wide gene expression analysis of control and treated NBL-W-S NB cells. 15231663 2004
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.070 Biomarker disease BEFREE In an effort to identify the genes and biological pathways that are responsible for the impaired NB tumor growth observed after treatment with 5-Aza-dC, we performed genome-wide gene expression analysis of control and treated NBL-W-S NB cells. 15231663 2004
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.070 Biomarker disease BEFREE The effect of MYCN down-regulation on MRP expression and response to cytotoxic drugs was investigated in NBL-S neuroblastoma cells transfected with MYCN antisense RNA constructs. 10348353 1999
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.070 Biomarker disease BEFREE The effect of MYCN down-regulation on MRP expression and response to cytotoxic drugs was investigated in NBL-S neuroblastoma cells transfected with MYCN antisense RNA constructs. 10348353 1999
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.070 Biomarker disease BEFREE The effect of MYCN down-regulation on MRP expression and response to cytotoxic drugs was investigated in NBL-S neuroblastoma cells transfected with MYCN antisense RNA constructs. 10348353 1999
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.070 Biomarker disease BEFREE Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP). 9516824 1997
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.070 GeneticVariation disease BEFREE Despite the excellent prognosis for neuroblastoma 4S (NBL 4S; with S indicating "special"), 10-25% of these patients nevertheless do not survive. 9307181 1997
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.070 Biomarker disease BEFREE Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP). 9516824 1997
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.070 GeneticVariation disease BEFREE Despite the excellent prognosis for neuroblastoma 4S (NBL 4S; with S indicating "special"), 10-25% of these patients nevertheless do not survive. 9307181 1997
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.070 GeneticVariation disease BEFREE Despite the excellent prognosis for neuroblastoma 4S (NBL 4S; with S indicating "special"), 10-25% of these patients nevertheless do not survive. 9307181 1997
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.070 Biomarker disease BEFREE Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP). 9516824 1997
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.070 AlteredExpression disease BEFREE Interestingly, the half-life of the N-myc protein in NBL-S is prolonged (approximately 100 min) compared to the short N-myc protein half-life previously described in N-myc amplified NB cell lines (approximately 30 min). 2284101 1990
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.070 AlteredExpression disease BEFREE Interestingly, the half-life of the N-myc protein in NBL-S is prolonged (approximately 100 min) compared to the short N-myc protein half-life previously described in N-myc amplified NB cell lines (approximately 30 min). 2284101 1990
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.070 AlteredExpression disease BEFREE Interestingly, the half-life of the N-myc protein in NBL-S is prolonged (approximately 100 min) compared to the short N-myc protein half-life previously described in N-myc amplified NB cell lines (approximately 30 min). 2284101 1990